Shinae Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shinae Yu has a total of 182 co-authors. Here are the top co-authors by number of shared publications:
- Sollip Kim
Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Institute of Digital Healthcare, University of Ulsan College of Medicine, Seoul, Korea
11 shared publications - Eun-Jung Cho
Department of Laboratory Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea
8 shared publications - Kyung Ran Jun
Department of Laboratory Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
8 shared publications Hyosoon Park
Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
6 shared publications- Kyung-Hwa Shin
Department of Laboratory Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea
6 shared publications - Eun-Suk Kang
Department of Laboratory Medicine and Genetics, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea
5 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Korean Association of Quality Assurance for Clinical Laboratory in Journal of Laboratory Medicine and Quality Assurance
- Vol. 48 (3) , 111-118
Quantitative Allergy Testing in Korea: Current Status and Diversification of External Quality Assessment Items
Hyeyoung Lee, Shinae Yu, Hyun Ji Lee, and Kyung-Hwa Shin. Lab Med Qual Assur 2026;48:111-8. https://doi.org/10.15263/jlmqa.2026.48.3.111
- 30 September 2026
- Published by Korean Association of Quality Assurance for Clinical Laboratory in Journal of Laboratory Medicine and Quality Assurance
- Vol. 48 (3) , 111-118
Open AccessQuantitative Allergy Testing in Korea: Current Status and Diversification of External Quality Assessment Items
Hyeyoung Lee, Shinae Yu, Hyun Ji Lee, and Kyung-Hwa Shin. Lab Med Qual Assur 2026;48:111-8. https://doi.org/10.15263/jlmqa.2026.48.3.111
- Open Access
- 23 September 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
Nationwide Multicenter Laboratory-Based Analysis of Varicella-Zoster Virus IgG and IgM Seropositivity in Korea, 2014–2024
Hae In Bang, M.D., Ph.D., Anna Lee, M.D., Ph.D., Jiwon Lee, M.D., Ph.D., Shinae Yu, M.D., Ph.D., Hyun-Woo Choi, M.D., Ph.D., Soo Jin Yoo, M.D., Ph.D., Young Ree Kim, M.D., Ph.D., Ji Hyun Kim, B.S., and Hyun Soo Kim, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0003
- 23 September 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
Open AccessNationwide Multicenter Laboratory-Based Analysis of Varicella-Zoster Virus IgG and IgM Seropositivity in Korea, 2014–2024
Hae In Bang, M.D., Ph.D., Anna Lee, M.D., Ph.D., Jiwon Lee, M.D., Ph.D., Shinae Yu, M.D., Ph.D., Hyun-Woo Choi, M.D., Ph.D., Soo Jin Yoo, M.D., Ph.D., Young Ree Kim, M.D., Ph.D., Ji Hyun Kim, B.S., and Hyun Soo Kim, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0003
- Open Access
- 21 September 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Development and Multicenter Validation of SNOMED CT–Mapped Implementation Value Set for Specimen Type in Clinical Laboratories (Preprint)
BACKGROUND Variability in local specimen type naming remains a barrier to semantic interoperability in laboratory data exchange. Standardized representation of specimen type as a distinct data element is needed to support interoperable laboratory information. OBJECTIVE This study aimed to develop and validate a clinically curated, SNOMED CT–mapped specimen type value set for implementation in the Korea Core Data for Interoperability (KR CDI). METHODS Local specimen type names were collected from six Korean institutions in May 2025. After exclusion of non-specimen, duplicate, and institution-specific terms, representative specimen terms were established by expert consensus and mapped to the SNOMED CT International Edition (2025-10-01). Coverage was assessed against a previously developed Logical Observation Identifiers Names and Codes (LOINC) reference set. External validation was performed at two independent university hospitals by assessing the applicability of the value-set terms and mapping local specimen terms to the value set. RESULTS Among 1,065 collected specimen type names, 659 curated local terms were consolidated into 174 representative terms across 24 categories. Of these, 136 (78.2%) were exactly mapped to a single SNOMED CT concept, 22 (12.6%) were represented using post-coordinated expressions, 14 (8.0%) were broadly mapped, and 2 (1.1%) were narrowly mapped. Thus, 158 of 174 terms (90.8%) were represented by either a single equivalent concept or post-coordination. External validation identified 73 (42.0%) and 130 (74.7%) of the 174 value-set terms as applicable at the two institutions, respectively. Of the local specimen terms evaluated, 75 of 647 (11.6%) and 279 of 295 (94.6%), respectively, were successfully mapped to the value set. CONCLUSIONS We developed a clinically curated, SNOMED CT–mapped specimen type value set for KR CDI. Most representative specimen terms could be represented by existing SNOMED CT concepts or post-coordinated expressions, while external validation showed substantial variation in local terminology and mapping coverage between institutions. The value set may support standardized representation of specimen type information for interoperable laboratory data exchange. Broader validation and mapping guidance for complex local specimen terms are needed to support implementation across diverse healthcare settings. CLINICALTRIAL SNOMED CT; specimen type; semantic interoperability; terminology standardization; laboratory medicine
- 21 September 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDevelopment and Multicenter Validation of SNOMED CT–Mapped Implementation Value Set for Specimen Type in Clinical Laboratories (Preprint)
BACKGROUND Variability in local specimen type naming remains a barrier to semantic interoperability in laboratory data exchange. Standardized representation of specimen type as a distinct data element is needed to support interoperable laboratory information. OBJECTIVE This study aimed to develop and validate a clinically curated, SNOMED CT–mapped specimen type value set for implementation in the Korea Core Data for Interoperability (KR CDI). METHODS Local specimen type names were collected from six Korean institutions in May 2025. After exclusion of non-specimen, duplicate, and institution-specific terms, representative specimen terms were established by expert consensus and mapped to the SNOMED CT International Edition (2025-10-01). Coverage was assessed against a previously developed Logical Observation Identifiers Names and Codes (LOINC) reference set. External validation was performed at two independent university hospitals by assessing the applicability of the value-set terms and mapping local specimen terms to the value set. RESULTS Among 1,065 collected specimen type names, 659 curated local terms were consolidated into 174 representative terms across 24 categories. Of these, 136 (78.2%) were exactly mapped to a single SNOMED CT concept, 22 (12.6%) were represented using post-coordinated expressions, 14 (8.0%) were broadly mapped, and 2 (1.1%) were narrowly mapped. Thus, 158 of 174 terms (90.8%) were represented by either a single equivalent concept or post-coordination. External validation identified 73 (42.0%) and 130 (74.7%) of the 174 value-set terms as applicable at the two institutions, respectively. Of the local specimen terms evaluated, 75 of 647 (11.6%) and 279 of 295 (94.6%), respectively, were successfully mapped to the value set. CONCLUSIONS We developed a clinically curated, SNOMED CT–mapped specimen type value set for KR CDI. Most representative specimen terms could be represented by existing SNOMED CT concepts or post-coordinated expressions, while external validation showed substantial variation in local terminology and mapping coverage between institutions. The value set may support standardized representation of specimen type information for interoperable laboratory data exchange. Broader validation and mapping guidance for complex local specimen terms are needed to support implementation across diverse healthcare settings. CLINICALTRIAL SNOMED CT; specimen type; semantic interoperability; terminology standardization; laboratory medicine
- Open Access
- 10 August 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
Implications of Incorporating Myelodysplasia-Related Gene Variant Data on Acute Myeloid Leukemia Reclassification According to WHO-HAEM5 and ICC: A Large Multicenter Korean Cohort Study
Yu Jeong Choi, M.D., Ph.D., Jee-Soo Lee, M.D., Ph.D., Saeam Shin, M.D., Ph.D., In-Suk Kim, M.D., Ph.D., Hyun-Young Kim, M.D., Ph.D., Boram Kim, M.D., Ph.D., Hee-Jin Kim, M.D., Ph.D., Eunhui Ji, M.D., Ph.D., Hyerin Kim, M.D., Ph.D., Hyerim Kim, M.D., Ph.D., Byunggyu Bae, M.D., Ph.D., Yonggoo Kim, M.D., Ph.D., Jong-Mi Lee, M.D., Ph.D., Yoon Hwan Chang, M.D., Ph.D., Hyun Kyung Kim, M.D., Ph.D., Ja Young Lee, M.D., Ph.D., Shinae Yu, M.D., Ph.D., Miyoung Kim, M.D., Ph.D., Young-Uk Cho, M.D., Ph.D., Seongsoo Jang, M.D., Ph.D., and Myungshin Kim, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0043
- 10 August 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
Open AccessImplications of Incorporating Myelodysplasia-Related Gene Variant Data on Acute Myeloid Leukemia Reclassification According to WHO-HAEM5 and ICC: A Large Multicenter Korean Cohort Study
Yu Jeong Choi, M.D., Ph.D., Jee-Soo Lee, M.D., Ph.D., Saeam Shin, M.D., Ph.D., In-Suk Kim, M.D., Ph.D., Hyun-Young Kim, M.D., Ph.D., Boram Kim, M.D., Ph.D., Hee-Jin Kim, M.D., Ph.D., Eunhui Ji, M.D., Ph.D., Hyerin Kim, M.D., Ph.D., Hyerim Kim, M.D., Ph.D., Byunggyu Bae, M.D., Ph.D., Yonggoo Kim, M.D., Ph.D., Jong-Mi Lee, M.D., Ph.D., Yoon Hwan Chang, M.D., Ph.D., Hyun Kyung Kim, M.D., Ph.D., Ja Young Lee, M.D., Ph.D., Shinae Yu, M.D., Ph.D., Miyoung Kim, M.D., Ph.D., Young-Uk Cho, M.D., Ph.D., Seongsoo Jang, M.D., Ph.D., and Myungshin Kim, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0043
- Open Access
- 4 June 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 46 (5) , 507-523
Essential Data Elements for Laboratory Test Interoperability: An Expert Consensus-Based Framework
Ha Nui Kim, M.D., Min-Sun Kim, M.D., Sollip Kim, M.D., Kuenyoul Park, M.D., Eun-Jung Cho, M.D., Hyejin Ryu, M.D., YeJin Oh, M.D., Shinae Yu, M.D., John Hoon Rim, M.D., Sang-Mi Kim, M.D., Geon Park, M.D., Jaehyeon Lee, M.D., Hyun-Seung Lee, M.D., Hyun-Woo Choi, M.D., You Kyoung Lee, M.D., Jeong Hwan Shin, M.D., Sang-Guk Lee, M.D., Young Kyung Lee, M.D., Jeong-Yeal Ahn, M.D., Sail Chun, M.D., Jungchan Park, M.D., Jong-Yeup Kim, M.D., Hye Hyeon Kim, Ph.D., AeKyung Kwon, M.S., Kyunghoon Lee, M.D., Yeo-Min Yun, M.D., Dongheui An, M.D., Soyoun Shin, M.D., HyunYoung Ji, M.D., On behalf of the Standardization Management Committee of the Laboratory Medicine Foundation, and On behalf of the Clinical Practice Guidelines Committee of the Korean Society for Laboratory Medicine. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0051
- 4 June 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 46 (5) , 507-523
Open AccessEssential Data Elements for Laboratory Test Interoperability: An Expert Consensus-Based Framework
Ha Nui Kim, M.D., Min-Sun Kim, M.D., Sollip Kim, M.D., Kuenyoul Park, M.D., Eun-Jung Cho, M.D., Hyejin Ryu, M.D., YeJin Oh, M.D., Shinae Yu, M.D., John Hoon Rim, M.D., Sang-Mi Kim, M.D., Geon Park, M.D., Jaehyeon Lee, M.D., Hyun-Seung Lee, M.D., Hyun-Woo Choi, M.D., You Kyoung Lee, M.D., Jeong Hwan Shin, M.D., Sang-Guk Lee, M.D., Young Kyung Lee, M.D., Jeong-Yeal Ahn, M.D., Sail Chun, M.D., Jungchan Park, M.D., Jong-Yeup Kim, M.D., Hye Hyeon Kim, Ph.D., AeKyung Kwon, M.S., Kyunghoon Lee, M.D., Yeo-Min Yun, M.D., Dongheui An, M.D., Soyoun Shin, M.D., HyunYoung Ji, M.D., On behalf of the Standardization Management Committee of the Laboratory Medicine Foundation, and On behalf of the Clinical Practice Guidelines Committee of the Korean Society for Laboratory Medicine. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0051
- Open Access
- 1 April 2026
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 16 (2) , 150-157
Current Status and Standardization Strategies for Major Infectious Antigen and Antibody Test Names in Korea
Kyung Ran Jun, M.D., Shinae Yu, M.D., Hae In Bang, M.D., Kyung-Hwa Shin, M.D., Hyeyoung Lee, M.D., Soo Jin Yoo, M.D.. Lab Med Online 2026;16:150-7. https://doi.org/10.47429/lmo.2026.16.2.150
- 1 April 2026
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 16 (2) , 150-157
Open AccessCurrent Status and Standardization Strategies for Major Infectious Antigen and Antibody Test Names in Korea
Kyung Ran Jun, M.D., Shinae Yu, M.D., Hae In Bang, M.D., Kyung-Hwa Shin, M.D., Hyeyoung Lee, M.D., Soo Jin Yoo, M.D.. Lab Med Online 2026;16:150-7. https://doi.org/10.47429/lmo.2026.16.2.150
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (18) , e137
Proposal for Modified Alpha Fetoprotein Use in Hepatocellular Carcinoma Surveillance: Analysis of the 2018–2020 National Cancer Screening Program
Yu S, et al. J Korean Med Sci. 2026 May;41:e137. https://doi.org/10.3346/jkms.2026.41.e137
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (18) , e137
Open AccessProposal for Modified Alpha Fetoprotein Use in Hepatocellular Carcinoma Surveillance: Analysis of the 2018–2020 National Cancer Screening Program
Yu S, et al. J Korean Med Sci. 2026 May;41:e137. https://doi.org/10.3346/jkms.2026.41.e137
- Open Access
- 31 December 2025
- Published by Kosin University College of Medicine in Kosin Medical Journal
- Vol. 40 (4) , 270-279
The ethics of using artificial intelligence in writing medical research papers
The rapid integration of large language models into medical publishing offers considerable potential for improving drafting efficiency but simultaneously raises substantial concerns regarding research integrity, accountability, and the reliability of the scientific record. Recent incidents in which artificial intelligence (AI) systems were listed as coauthors have prompted urgent regulatory revisions. In this review, we identify a global consensus that strictly prohibits AI authorship, as algorithms lack both moral agency and legal accountability. Transparency has emerged as an essential requirement, and undisclosed AI use is increasingly regarded as a form of ethical misconduct. Key risks include “hallucinations” (notably citation fabrication), algorithmic bias, and potential violations of privacy regulations (e.g., the Health Insurance Portability and Accountability Act) when protected health information is processed through cloud-based platforms. The analysis indicates that rigid prohibitions are operationally unenforceable, supporting instead a “human stewardship” model in which AI functions as a drafting scaffold subjected to rigorous human verification. AI represents a lasting transformation in medical writing that necessitates a shift from simple prohibition to structured governance. To preserve epistemic validity, we propose a framework built on task segmentation, mandatory cross-referencing of claims, and data sovereignty. Ultimately, AI must remain a transparent assistive tool, with full responsibility for the manuscript residing exclusively with the human investigator.
- 31 December 2025
- Published by Kosin University College of Medicine in Kosin Medical Journal
- Vol. 40 (4) , 270-279
Open AccessThe ethics of using artificial intelligence in writing medical research papers
The rapid integration of large language models into medical publishing offers considerable potential for improving drafting efficiency but simultaneously raises substantial concerns regarding research integrity, accountability, and the reliability of the scientific record. Recent incidents in which artificial intelligence (AI) systems were listed as coauthors have prompted urgent regulatory revisions. In this review, we identify a global consensus that strictly prohibits AI authorship, as algorithms lack both moral agency and legal accountability. Transparency has emerged as an essential requirement, and undisclosed AI use is increasingly regarded as a form of ethical misconduct. Key risks include “hallucinations” (notably citation fabrication), algorithmic bias, and potential violations of privacy regulations (e.g., the Health Insurance Portability and Accountability Act) when protected health information is processed through cloud-based platforms. The analysis indicates that rigid prohibitions are operationally unenforceable, supporting instead a “human stewardship” model in which AI functions as a drafting scaffold subjected to rigorous human verification. AI represents a lasting transformation in medical writing that necessitates a shift from simple prohibition to structured governance. To preserve epistemic validity, we propose a framework built on task segmentation, mandatory cross-referencing of claims, and data sovereignty. Ultimately, AI must remain a transparent assistive tool, with full responsibility for the manuscript residing exclusively with the human investigator.
- Open Access
- 2 October 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (19) , 2510
The Establishment of Reference Intervals for Thyroid Hormone Tests in the Korean Population: Using a Direct Selection Technique
Background/Objectives: Thyroid-stimulating hormone (TSH), free thyroxine (FT4), and total triiodothyronine (TT3) are biomarkers for evaluating thyroid function. Although hormone levels are affected by many biological and environmental factors, most laboratories use manufacturer-provided reference intervals (RIs) without considering these factors. Thus, in this study we assessed RIs for TSH, FT4, and TT3 in a Korean population, using a direct selection technique. Methods: Serum samples from patients without a history of thyroid disease, medication, family history, or antibody-positive test results were collected after a review of medical records. TSH, FT4, and TT3 levels were measured using the Cobas e801 analyzer (Roche Diagnostics GmbH, Mannheim, Germany) with dedicated reagents. RIs were then established using a non-parametric method, using values at the 2.5th and 97.5th percentiles as reference limits, which were then verified in a validation cohort. Results: A total of 618 subjects were enrolled in this study. Because the distribution of reference values for the four subgroups divided by sex and age (65 years) showed insignificant differences, combined RIs were determined, with the established RIs being 0.38–5.46 mIU/L for TSH, 12.28–22.40 pmol/L for FT4, and 0.94–2.32 nmol/L for TT3. When compared to manufacturer-claimed RIs, the Korean RI for TSH showed higher upper limits, while that for TT3 showed lower upper limits. Additionally, when newly established RIs were applied to the validation cohort, the rate of test-positive results decreased significantly. Conclusions: Significant differences in RIs for TSH and TT3 in the Korean population, compared to manufacturer-claimed values, highlight the need for population-specific RIs. Thus, interpreting the results for the Korean population requires caution, and Korean population-based RIs are necessary.
- 2 October 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (19) , 2510
Open AccessThe Establishment of Reference Intervals for Thyroid Hormone Tests in the Korean Population: Using a Direct Selection Technique
Background/Objectives: Thyroid-stimulating hormone (TSH), free thyroxine (FT4), and total triiodothyronine (TT3) are biomarkers for evaluating thyroid function. Although hormone levels are affected by many biological and environmental factors, most laboratories use manufacturer-provided reference intervals (RIs) without considering these factors. Thus, in this study we assessed RIs for TSH, FT4, and TT3 in a Korean population, using a direct selection technique. Methods: Serum samples from patients without a history of thyroid disease, medication, family history, or antibody-positive test results were collected after a review of medical records. TSH, FT4, and TT3 levels were measured using the Cobas e801 analyzer (Roche Diagnostics GmbH, Mannheim, Germany) with dedicated reagents. RIs were then established using a non-parametric method, using values at the 2.5th and 97.5th percentiles as reference limits, which were then verified in a validation cohort. Results: A total of 618 subjects were enrolled in this study. Because the distribution of reference values for the four subgroups divided by sex and age (65 years) showed insignificant differences, combined RIs were determined, with the established RIs being 0.38–5.46 mIU/L for TSH, 12.28–22.40 pmol/L for FT4, and 0.94–2.32 nmol/L for TT3. When compared to manufacturer-claimed RIs, the Korean RI for TSH showed higher upper limits, while that for TT3 showed lower upper limits. Additionally, when newly established RIs were applied to the validation cohort, the rate of test-positive results decreased significantly. Conclusions: Significant differences in RIs for TSH and TT3 in the Korean population, compared to manufacturer-claimed values, highlight the need for population-specific RIs. Thus, interpreting the results for the Korean population requires caution, and Korean population-based RIs are necessary.